Use of the rat pancreatic ca20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy

Nuclear Medicine Communications

Volumn 21, Issue 11, 2008, Pages 1079-1085

  Bernard, B F ^a   Krenning, E ^a   Breeman, W A P ^a   Visser, T J ^b   Bakker, W H ^b   Srinivasan, A ^b   De Jong, M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85044555518     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200011000-00015     Document Type: Review

References (31)

1. 3] octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
2. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998; 58: 437-441.
3. Slooter GD, Breeman WAP, Marquet RL, Krenning EP, Eijck van CHJ. The antiproliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer 1999; 81: 767-771.
4. Krenning EP, Jong M de, Kooij PPM et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999; 10(suppl 2): S23-S29.
5. Jong M de, Breeman WAP, Bernard HF et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med 1999; 43: 356-366.
6. Otte A, Jermann E, Béhé M et al. Dotatoc: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24: 792-795.
7. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Hermann R, Maecke HR. Yttrium-90 labeled somatostatin analogue for cancer treatment. Lancet 1998; 351: 417-418.
8. 90Y-SMT 487) eradicates experimental rat pancreatic CA20948 tumours. Eur J Nucl Med 1998; 7: 668-674.
9. Reubi JC, Waser B, Schaer JC et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 1998; 25: 481-490.
10. Breeman WAP, Hofland LJ, Jong de M et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 1999; 81: 658-665.
11. 1]substance P. J Nucl Med 1996; 37: 108-117.
12. Anderson CJ, Jones LA, Bass LA et al. Radiotherapy, toxicity and dosimetry of Cu-64-TETA-octreotide in tumour-bearing rats. J Nucl Med 1998; 39: 1944-1951.
13. Bakker WH, Krenning EP, Breeman WAP et al. Receptor scintigraphy with a radioiodinated somatostatin analog: radiolabelling, purification, biologic activity, and in vivo application in animals. J Nucl Med 1990; 31: 1501-1509.
14. 3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 1998; 19: 283-288.
15. 1]octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumours: synthesis, radiolabelling and in vitro validation. Life Sci 1991; 49: 844-852.
16. Christophe J. Pancreatic tumoural cell line AR42J: an amphricine model. Am Phys Soc 1994; 266: G963-971.
17. 8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 1999; 12: 2081-2087.
18. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci 1995; 57: 1249-1265.
19. Reubi J-C, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumours using in situ hybridization. Cancer Res 1994; 54: 3455-3459.
20. Reubi JC, Schaer JC, Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptor in human tumours. Cancer Res 1997; 57: 1377-1386.
21. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991; 64: 567-573.
22. Kwekkeboom DJ, Reubi J-C, Lamberts SWJ et al. in vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993; 76: 1413-1417.
23. Behr TM, Jenner N, Béhé M et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999; 40: 1029-1044.
24. Mantyh CR, Gates TS, Zimmerman RP et al. Receptor binding sites for substance P, but substance K or neuromidin K, are expressed in high concentrations by arterioles, venules, and lymph nodes in surgical specimens from patients with ulcerative colitis and Crohn’s disease. Proc Natl Acad Sci USA 1988; 85: 3235-3239.
25. 4)bombesin by tumor cells. Prostate 1994; 25: 29-38.
26. Markwalder R, Reubi J-C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999; 59: 1152-1159.
27. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111 diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumour cell, renal and hepatocyte lysosomes. Cancer Res 1997; 57: 659-671.
28. 4]bombesin, a new radioligand for bombesin receptor scintigraphy. Int J Cancer 1999; 83(5): 657-663.
29. Jong de M, Rolleman EJ, Bernard HF et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996; 37: 1388-1392.
30. 90Y octreotide renal uptake. J Nucl Med 1997; 38: 1929-1933.
31. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998; 25: 210-212.